Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares

What other to cognize

• This was a caller presumption for Patient Square Capital LP and represented 2.68% of its reportable AUM astatine quarter-end

• Top 5 holdings aft the filing:

  • NASDAQ: ROIV: $226,199,502 (40.1% of AUM)

  • NASDAQ: ARGX: $26,813,320 (4.8% of AUM)

  • NASDAQ: INSM: $25,754,400 (4.6% of AUM)

  • NASDAQ: ONC: $23,918,558 (4.2% of AUM)

  • NASDAQ: COGT: $22,940,040 (4.1% of AUM)

• As of May 14, 2026, shares of Nektar Therapeutics were priced astatine $74.33, up 669.46% implicit the anterior year, outperforming the S&P 500 by 642.16 percent points

Company overview

Company snapshot

• Nektar Therapeutics develops biopharmaceutical products targeting oncology, immunology, and inflammatory diseases, with pb candidates including Bempegaldesleukin and NKTR-358 successful objective trials for crab and autoimmune disorders.

• Its superior partners are planetary pharmaceutical firms seeking innovative therapies for unmet aesculapian needs.

• The institution is headquartered successful San Francisco, California, and leverages expertise successful cytokine engineering and immunomodulation.

Nektar Therapeutics is simply a clinical-stage biotechnology institution focused connected advancing caller immunotherapies for crab and autoimmune conditions. Leveraging a robust pipeline and strategical collaborations with starring pharmaceutical companies, Nektar aims to code important gaps successful existent attraction options. The company's expertise successful cytokine engineering and immunomodulation positions it arsenic a cardinal innovator wrong the biotechnology sector.

What this transaction means for investors

If Patient Square acquired its caller Nektar Therapeutics Position successful the archetypal fractional of the archetypal quarter, it was a precise lucrative stake for the firm. Shares of the biopharmaceutical institution much than doubled successful February aft the institution reported palmy results from the signifier 2b Rezolve-AD objective trial, which treated eczema patients with rezpegaldesleukin.

Rezpegaldesleukin is an experimental attraction that targets interleukin-2 receptors. It boosts accumulation of regulatory T cells that look to forestall patients’ immune systems from mistakenly attacking steadfast tegument tissue.